411 related articles for article (PubMed ID: 17373219)
61. [Anderson-Fabry disease].
Kes P; Basić-Jukić N; Brunetta B; Jurić I
Acta Med Croatica; 2006; 60(1):55-8. PubMed ID: 16802573
[TBL] [Abstract][Full Text] [Related]
62. [Fabry disease].
Feriozzi S; Faraggiana T
G Ital Nefrol; 2005; 22 Suppl 33():S34-8. PubMed ID: 16419004
[TBL] [Abstract][Full Text] [Related]
63. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
64. Fabry disease.
Schiffmann R
Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
[TBL] [Abstract][Full Text] [Related]
65. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
66. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
Schiffmann R; Kopp JB; Austin HA; Sabnis S; Moore DF; Weibel T; Balow JE; Brady RO
JAMA; 2001 Jun; 285(21):2743-9. PubMed ID: 11386930
[TBL] [Abstract][Full Text] [Related]
67. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
[TBL] [Abstract][Full Text] [Related]
68. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
69. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
[TBL] [Abstract][Full Text] [Related]
70. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
[TBL] [Abstract][Full Text] [Related]
71. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Banikazemi M; Ullman T; Desnick RJ
Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
[TBL] [Abstract][Full Text] [Related]
72. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
Ishii S; Chang HH; Yoshioka H; Shimada T; Mannen K; Higuchi Y; Taguchi A; Fan JQ
J Pharmacol Exp Ther; 2009 Mar; 328(3):723-31. PubMed ID: 19106170
[TBL] [Abstract][Full Text] [Related]
73. Fabry disease: clinical features and recent advances in enzyme replacement therapy.
Desnick RJ; Wasserstein MP
Adv Nephrol Necker Hosp; 2001; 31():317-39. PubMed ID: 11692469
[No Abstract] [Full Text] [Related]
74. [Clinical courses of two male siblings on hemodialysis for Fabry disease ].
Itoh K; Tanaka M; Matsushita K; Miyamura N; Nishida K; Araki E; Nonoguchi H; Tomita K
Nihon Jinzo Gakkai Shi; 2005; 47(2):121-7. PubMed ID: 15859134
[TBL] [Abstract][Full Text] [Related]
75. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.
Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM
Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076
[TBL] [Abstract][Full Text] [Related]
76. The Fabry cardiomyopathy: models for the cardiologist.
Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
[TBL] [Abstract][Full Text] [Related]
77. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.
Tosoni A; Nebuloni M; Zerbi P; Vago L; Comotti C; Sessa A
Ultrastruct Pathol; 2005; 29(3-4):203-7. PubMed ID: 16036875
[TBL] [Abstract][Full Text] [Related]
78. [Neurological manifestations of Fabry disease].
Mendióroz M; Fernández-Cadenas I; Montaner J
Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
[TBL] [Abstract][Full Text] [Related]
79. Fabry disease. A case report.
Kotnik J; Kotnik F; Desnick RJ
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
[TBL] [Abstract][Full Text] [Related]
80. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]